Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biologics and Small Molecule Agents in Allergic and Immunologic Skin Diseases
Authors
Keywords
Immunologic skin disease, Psoriasis, Atopic dermatitis, Biologics, Small molecules
Journal
CURRENT ALLERGY AND ASTHMA REPORTS
Volume 18, Issue 10, Pages -
Publisher
Springer Nature America, Inc
Online
2018-08-31
DOI
10.1007/s11882-018-0804-8
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3)
- (2018) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis
- (2018) Laura Sawyer et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
- (2018) Mark G. Lebwohl et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
- (2018) Lluís Puig et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Serlopitant for the treatment of chronic pruritus: Results of a randomized, multicenter, placebo-controlled phase 2 clinical trial
- (2018) Gil Yosipovitch et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparative effectiveness of targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis
- (2018) Anne M. Loos et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
- (2018) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)
- (2018) R. Bissonnette et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from the LIBERATE study
- (2018) K. Reich et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
- (2018) K.A. Papp et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials
- (2018) A.B. Gottlieb et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment
- (2017) Emma Guttman-Yassky et al. EXPERIMENTAL DERMATOLOGY
- Old and New Biological Therapies for Psoriasis
- (2017) Kirsten Rønholt et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies
- (2017) Patrick M. Brunner et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis
- (2017) Steven R. Feldman et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
- (2017) Alice Gottlieb et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
- (2017) Joseph F. Merola et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
- (2017) Jerry Bagel et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial
- (2017) Kristian Reich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)
- (2017) Andrew Blauvelt et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis
- (2017) K. Reich et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3
- (2017) C.L. Leonardi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Impact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials
- (2017) L. Guenther et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study
- (2017) A. Blauvelt et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Impact of ixekizumab on facial psoriasis and related quality of life measures in moderate-to-severe psoriasis patients: 12-week results from two phase III trials
- (2017) C. Paul et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study
- (2017) R. Bissonnette et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate-to-severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, UNCOVER-2 and UNCOVER-3)
- (2017) A. Menter et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials
- (2017) Kristian Reich et al. LANCET
- Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
- (2017) Andrew Blauvelt et al. LANCET
- Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
- (2017) Thomas Ruzicka et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of Ixekizumab Treatment on Depressive Symptoms and Systemic Inflammation in Patients with Moderate-to-Severe Psoriasis: An Integrated Analysis of Three Phase 3 Clinical Studies
- (2017) Christopher E.M. Griffiths et al. PSYCHOTHERAPY AND PSYCHOSOMATICS
- Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis
- (2016) J Sobell et al. ACTA DERMATO-VENEREOLOGICA
- Investigation of selective JAK1 inhibitor GSK2586184 for the treatment of psoriasis in a randomized placebo-controlled phase IIa study
- (2016) V.J. Ludbrook et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis
- (2016) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
- (2016) Saakshi Khattri et al. EXPERIMENTAL DERMATOLOGY
- Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials
- (2016) Bruce Strober et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Efficacy of omalizumab in patients with atopic dermatitis: A systematic review and meta-analysis
- (2016) Hsiao-Han Wang et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cellular and molecular immunologic mechanisms in patients with atopic dermatitis
- (2016) Thomas Werfel et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis
- (2016) Mohn’d AbuHilal et al. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
- Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis
- (2016) Neil J. Korman et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis
- (2016) April W. Armstrong et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2)
- (2016) Phoebe Rich et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials
- (2016) D. Thaçi et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient-reported outcomes from a Phase 3 study
- (2016) F. Valenzuela et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3
- (2016) P. van de Kerkhof et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
- (2016) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of Immunobiologic and Small Molecule Inhibitor Drugs for Psoriasis: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- (2016) André Vicente Esteves de Carvalho et al. Drugs in research & development
- Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis
- (2016) April W. Armstrong et al. JAMA Dermatology
- A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis
- (2015) K. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
- (2015) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co
- (2015) O. Nemoto et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)
- (2015) C. Paul et al. BRITISH JOURNAL OF DERMATOLOGY
- The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization
- (2015) Shinji Noda et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
- (2015) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials
- (2015) Christopher E M Griffiths et al. LANCET
- Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial
- (2015) Hervé Bachelez et al. LANCET
- Multi-ancestry genome-wide association study of 21,000 cases and 95,000 controls identifies new risk loci for atopic dermatitis
- (2015) Lavinia Paternoster et al. NATURE GENETICS
- Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
- (2015) Mark Lebwohl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of brodalumab for psoriasis after 120 weeks of treatment
- (2014) Kim Papp et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
- (2014) Lisa A. Beck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials
- (2014) Richard G. Langley et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immunologic Effects of Omalizumab in Children with Severe Refractory Atopic Dermatitis: A Randomized, Placebo-Controlled Clinical Trial
- (2013) Shuba Rajashri Iyengar et al. INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
- The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses
- (2013) Michelle A. Lowes et al. TRENDS IN IMMUNOLOGY
- IL-31 Expression by Inflammatory Cells is Preferentially Elevated in Atopic Dermatitis
- (2012) GFL Hofbauer et al. ACTA DERMATO-VENEREOLOGICA
- A Pilot Study of an Oral Phosphodiesterase Inhibitor (Apremilast) for Atopic Dermatitis in Adults
- (2012) Aman Samrao et al. ARCHIVES OF DERMATOLOGY
- Apremilast mechanism of action and application to psoriasis and psoriatic arthritis
- (2012) Peter Schafer BIOCHEMICAL PHARMACOLOGY
- Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab′ certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension
- (2012) K. Reich et al. BRITISH JOURNAL OF DERMATOLOGY
- Association of distinct IL-31 polymorphisms with pruritus and severity of atopic dermatitis
- (2012) M. Sokołowska-Wojdyło et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Pharmacological and therapeutic effects of A3 adenosine receptor agonists
- (2011) Pnina Fishman et al. DRUG DISCOVERY TODAY
- An update on the genetics of atopic dermatitis: Scratching the surface in 2009
- (2010) Kathleen C. Barnes JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Cytokine modulation of atopic dermatitis filaggrin skin expression
- (2009) Michael D. Howell et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
- (2008) Byung Eui Kim et al. CLINICAL IMMUNOLOGY
- Th2 Cytokines Act on S100/A11 to Downregulate Keratinocyte Differentiation
- (2008) Michael D. Howell et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now